GANTouch: An Attack-Resilient Framework for Touch-based Continuous Authentication System

Previous studies have shown that commonly studied (vanilla) implementations of touch-based continuous authentication systems (V-TCAS) are susceptible to active adversarial attempts. This study presents a novel Generative Adversarial Network assisted TCAS (G-TCAS) framework and compares it to the V-TCAS under three active adversarial environments viz. Zero-effort, Population, and Random-vector. The Zero-effort environment was implemented in two variations viz. Zero-effort (same-dataset) and Zero-effort (cross-dataset). The first involved a Zero-effort attack from the same dataset, while the second used three different datasets. G-TCAS showed more resilience than V-TCAS under the Population and Random-vector, the more damaging adversarial scenarios than the Zero-effort. On average, the increase in the false accept rates (FARs) for V-TCAS was much higher (27.5% and 21.5%) than for G-TCAS (14% and 12.5%) for Population and Random-vector attacks, respectively. Moreover, we performed a fairness analysis of TCAS for different genders and found TCAS to be fair across genders. The findings suggest that we should evaluate TCAS under active adversarial environments and affirm the usefulness of GANs in the TCAS pipeline.

Defending Touch-based Continuous Authentication Systems from Active Adversaries Using Generative Adversarial Networks

Previous studies have demonstrated that commonly studied (vanilla) touch-based continuous authentication systems (V-TCAS) are susceptible to population attack. This paper proposes a novel Generative Adversarial Network assisted TCAS (G-TCAS) framework, which showed more resilience to the population attack. G-TCAS framework was tested on a dataset of 117 users who interacted with a smartphone and tablet pair. On average, the increase in the false accept rates (FARs) for V-TCAS was much higher (22%) than G-TCAS (13%) for the smartphone. Likewise, the increase in the FARs for V-TCAS was 25% compared to G-TCAS (6%) for the tablet.